Epratuzumab Y-90

Drug Profile

Epratuzumab Y-90

Alternative Names: 90Y-DOTA-hLL2; 90Y-Epratuzumab; 90Y-hLL2; 90Y-hLL2 IgG; Anti-CD22 monoclonal antibody LL2-Y-90; hCD22-Y-90; IMMU-102; Monoclonal antibody LL2-Y-90; Y-90 epratuzumab tetraxetan; Yttrium-90 epratuzumab tetraxetan; Yttrium-90-labelled epratuzumab

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Nantes University Hospital
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD22 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 17 Jan 2017 Nantes University Hospital withdraws the phase I/II EPRALLO trial prior to enrolment for Acute lymphoblastic leukaemia in France (NCT02577094)
  • 26 Oct 2015 Nantes University Hospital plans the phase I/II EPRALLO trial for Acute lymphoblastic leukaemia in France (NCT02577094)
  • 17 Aug 2015 Epratuzumab Y-90 is still in phase I/II trials for Acute lymphoblastic leukaemia (Second-line therapy or greater) in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top